Podcasts about nsclc

New FDA approvals and practice-relevant Phase III data feature in this week's Oncology Updates from ONCOassist.Dr. Stephanie Haddad, Hematology/Oncology Fellow and Academic Chief Fellow at UT Health San Antonio/Mays Cancer Center, covers:

Featuring an interview with Dr Alexander E Drilon, including the following topics: Overview of targetable biomarkers in lung cancer (0:00) Biomarker testing for genomic alterations in lung cancer (5:24) Overview of ROS1 alterations in lung cancer (13:44) Efficacy data with ROS1 inhibitors for lung cancer (17:02) Safety data with ROS1 inhibitors for lung cancer (21:15) Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56) Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16) Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52) NCPD information and select publications

In this episode of Targeted Talks, Benjamin Herzberg, MD, discusses the evolving treatment landscape for KRAS-mutant non–small cell lung cancer (NSCLC). He explains why KRAS matters to all oncologists, since these mutations drive roughly 30% of NSCLC cases, and reviews why chemoimmunotherapy remains the first-line standard of care for now. He also covers how central nervous system metastases affect treatment planning and why close collaboration with pathology and upfront biomarker testing are essential. Herzberg then turns to the pan-RAS inhibitor daraxonrasib (Rasonque), recently approved in pancreatic cancer, and explains why lung cancer clinicians should pay attention. He discusses its published lung cancer data, which show response rates and durability similar to those in pancreatic cancer, as well as the ongoing phase 3 trial vs docetaxel. He also discusses zoldonrasib, a G12D-specific inhibitor with a favorable tolerability profile, and the idea of a "RAS toolkit" of pan-RAS and allele-specific agents. He closes with the biggest unmet needs, including driver-negative disease and resistance to targeted therapy, and what excites him most: molecular glues and other novel drug modalities, including MTAP/PRMT5 inhibitors.

National Comprehensive Cancer Network Guidelines for Lung Cancer & Managed Care On this episode host Steve Kheloussi, PharmD, principal consultant with Kheloussi Consulting and a managed care pharmacist, is joined by Tianyi Wang, consultant at Omnicom Health Market Access, and Irvin Molina, PharmD, BCOP, director of clinical pharmacy at IPD Analytics and a board-certified oncology pharmacist, to explore how National Comprehensive Cancer Network (NCCN) guidelines influence payer policy and patient access in non-small cell lung cancer (NSCLC).

In today's episode, Narjust Florez, MD, and Jonathan Wesley Riess, MD, MS, hosted a discussion about the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer (NSCLC). Dr Florez is the associate medical director of the Cancer Care Access Program and a physician at Dana-Farber Cancer Institute, as well as an assistant professor of medicine and a faculty member at Harvard Medical School, both in Boston, Massachusetts. Dr Riess is the director of Thoracic Oncology and an associate professor of medicine in the Division of Hematology and Oncology at the University of California (UC) Davis Health Medical Center and the UC Davis Comprehensive Cancer Center in Sacramento.In our exclusive interview, Drs Florez and Riess clarified that HER2 mutations, commonly exon 20 insertions, are genomic drivers sensitive to TKIs, whereas HER2 overexpression is a protein finding identified by immunohistochemistry (IHC). They discussed the use of fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with HER2 IHC 3+ NSCLC, reviewed efficacy data from the DESTINY-Lung studies, and worked through a treatment sequencing case. Their conversation also addressed toxicity management, particularly aggressive nausea prophylaxis and vigilance for interstitial lung disease, and emphasized the importance of upfront HER2 testing to preserve tissue and save time.

At WCLC 2026, three thoracic oncologists discuss first-line combinations, toxicity management, and subcutaneous amivantamab.

This content was funded by Johnson & Johnson. This material is intended for educational and scientific exchange purposes only. It is not intended to be promotional and should not be used to make treatment decisions for any individual patient. The views expressed are those of the speaker and do not necessarily reflect those of Johnson & Johnson.   Atypical EGFR mutations make up approximately 5 to 10% of EGFR-mutant NSCLC, and because some assays only report exon 19 deletions and L858R, they are easy to miss. In this short podcast, Melina Marmarelis, thoracic oncologist at the University of Pennsylvania, explains why these mutations often respond differently to EGFR TKIs and how to pick them up on NGS. She also walks through CHRYSALIS-2 Cohort C, which evaluated amivantamab plus lazertinib in treatment-naive and previously treated patients.   Explore: •    Why G719X and other atypical mutations alter the ATP-binding pocket differently from exon 19 del and L858R •    Which assays can miss atypical mutations, and when broader NGS is needed •    What CHRYSALIS-2 Cohort C evaluated, and the limitations of a single-arm phase 1/1b study •    How the ASCO living guideline now addresses atypical EGFR alterations   Amivantamab plus lazertinib is not approved by the US Food and Drug Administration for the treatment of atypical EGFR-mutated non-small cell lung cancer. This content includes discussion of investigational and unapproved uses. The data presented do not establish safety or efficacy for any unapproved use. Prescribers should consult the full Prescribing Information for approved indications and complete safety information.    Speaker: Melina E. Marmarelis, Associate Professor of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

In this series, the 2025-26 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.After her prognosis in the spring of 2024, LuAnne Sirdiak started writing. Not for herself, and not for the world — she created a private Facebook group called Life!, and invited people in. For three years she has documented the scans, the treatments, the waiting, and everything in between, for a group she chose.Music: Ester - Here (BenSound) License certificate #2242649

While most people are familiar with HER2 in regards to breast cancer,  there are HER2 mutations in lung cancer. On this episode of the ATS Breathe Easy podcast, host Patti Tripathi explores HER2-mutant non-small cell lung cancer (NSCLC), an uncommon but increasingly treatable form of lung cancer. Oncologist Christine Lovly, MD, PhD, City of Hope, explains the rapidly evolving science behind HER2 testing and targeted therapies, while patient Nicole Field shares her experience living with stage IV HER2-mutant lung cancer.For more resources, check out these organizations:LUNGevity Foundation: https://www.lungevity.org/International Cancer Advocacy Network: https://askican.org/Rexanna's Foundation: https://rexannasfoundation.org/

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of metastatic non–small cell lung cancer (NSCLC) diagnosis and management for 2026, reflecting the rapidly expanding treatment landscape that is growing to include chemotherapy, immunotherapy, and targeted agents.The discussion began with molecular workup, emphasizing the importance of conducting upfront multigene next-generation sequencing plus PD-L1 testing by immunohistochemistry (IHC) for all nonsquamous disease, with HER2 and c-MET IHC now part of routine evaluation. Drs Armstrong and Tawagi stressed that circulating tumor DNA complements but does not replace tissue biospy, and that a targetable driver generally prompts the initiation of first-line targeted therapy, except in the case of KRAS G12C and NRG1 fusions.Regarding EGFR-mutated disease, they reviewed 3 category 1 first-line options: osimertinib (Tagrisso) monotherapy, osimertinib plus chemotherapy, and amivantamab (Rybrevant) plus lazertinib (Lazcluze), cautioning against overlapping immunotherapy. They detailed post-osimertinib resistance testing and EGFR exon 20 insertions, then addressed ALK, ROS1, BRAF V600E, RET, MET exon 14, NTRK, and NRG1 alterations, noting preferred agents and characteristic toxicities, such as lorlatinib (Lorbrena)–associated hyperlipidemia.Drs Armstrong and Tawagi also covered HER2-directed therapies, including fam-trastuzumab deruxtecan-nxki (Enhertu), as well as antibody-drug conjugates for EGFR-mutated and c-MET–high disease. For driver-negative disease, they stratified first-line therapy by PD-L1 status and histology, discussing immunotherapy monotherapy, chemoimmunotherapy, and dual checkpoint blockade, before reviewing second-line options for patients with or without prior immunotherapy.

From the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Dr. Narjust Florez talks with Dr. Chad Rusthoven about MAVERICK, the trial that tested MRI surveillance alone against prophylactic cranial irradiation in small cell lung cancer, and with Dr. Chul Kim about the final overall survival results of PAPILLON, amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC. Both guests share what patients and community oncologists should take from the data. Guests: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Chad G. Rusthoven, MD Adjunct Associate Professor University of Colorado University of North Carolina at Chapel Hill

In this podcast, Wade T. Iams from the Greco-Hainsworth Centers for Research Tennessee Oncology, Nashville, TN, USA and Narjust Florez form the Dana-Farber Cancer Institute and the Harvard Medical School, Boston, MA, USA discuss safety considerations with MET TKI treatment for patients with METex14 skipping NSCLC. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01242-z. All conflicts of interest can be found online. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant advancements and challenges that are shaping the future of drug development, regulatory landscapes, and industry innovations. Starting with a major milestone in personalized cancer therapy, the FDA has expanded Bayer's approval for Hyrnuo (zipalertinib) to include its use as a first-line treatment for HER2-mutant non-small cell lung cancer (NSCLC). This approval is based on promising Phase 1/2 clinical data, highlighting zipalertinib's role as a tyrosine kinase inhibitor targeting specific genetic mutations. This development is part of a broader trend towards precision medicine in oncology, allowing treatments to be specifically tailored to patients' genetic profiles. The potential impact on patient care is substantial, offering more effective treatment options for those with this particular HER2 mutation. In parallel, Johnson & Johnson's Imbruvica (ibrutinib) regimen has been endorsed by NICE for mantle cell lymphoma. These advancements represent a significant shift towards integrating precision medicine into oncology, aiming to improve outcomes by focusing on individual patient needs. On the business front, Samsung Biologics has secured a $262 million manufacturing deal with an unnamed European pharmaceutical company. This highlights an increasing demand for biologics manufacturing capabilities and reflects a growing reliance on contract development and manufacturing organizations (CDMOs) to meet complex therapeutic needs. Meanwhile, EMD Serono's acquisition of PostEra's AI-discovered fertility programs marks a pivotal move towards incorporating artificial intelligence in drug discovery, potentially revolutionizing women's health and fertility treatments. Clinical trial successes continue to drive momentum in the sector. AbbVie's Qulipta (atogepant) achieved its primary endpoint in a Phase 3 trial focused on menstrual migraines through CGRP receptor antagonism. This positions Qulipta as a promising new therapy within neurological disorders. Similarly, Rezera's Ruvonoflast met its primary endpoint in treating peripheral artery disease via NLRP3 inhibition, showcasing innovative anti-inflammatory approaches within cardiovascular medicine. Investment remains robust across the industry landscape. Frazier Life Sciences has successfully raised $1.1 billion to support small to mid-cap biotech companies, aiming to foster innovation and support emerging firms through critical phases of drug development. Additionally, CordenPharma's €80 million investment in enhancing aseptic fill-finish capacity illustrates strategic expansions within pharmaceutical manufacturing infrastructure. However, regulatory challenges persist. NICE's rejection of Gilead Sciences' lenacapavir due to cost concerns underscores ongoing debates around drug pricing and accessibility within healthcare systems. Furthermore, Biohaven Pharmaceuticals faces a partial clinical hold by the FDA on its epilepsy drug trial due to safety concerns. These instances highlight the rigorous scrutiny required throughout drug development processes. In response to these challenges, companies are increasingly adopting sophisticated strategies to navigate the evolving regulatory landscape. The "most favored nation" pricing policy in the U.S., designed to align domestic drug prices with those abroad, is prompting pharmaceutical firms to reassess their market strategies amid shifting economic conditions. On an optimistic note, Encoded Therapeutics has raised $275 million in Series F financing aimed at advancing gene therapies for conditions like Dravet syndrome. This substantial investment underscores confidence in gene therapy as a transformative approach for treating complex neurological and rare diseases. Finally, Ionis Pharmaceuticals achieved a breakthrough with its therapy approval for Alexander disease, illustrating the growing emphasis on targeting genetic disorders through precision medicine approaches. Such developments reflect both the dynamic nature of scientific innovation and the inherent challenges that accompany it. As these advancements unfold across various therapeutic areas and technological innovations continue to transform industry practices, it becomes increasingly clear that strategic planning and investment in research are crucial for translating scientific breakthroughs into tangible patient benefits. The ability of companies to innovate while ensuring compliance and economic viability will be pivotal as they strive to redefine treatment paradigms within this highly competitive sector. Thank you for joining us today on Pharma Daily. Stay tuned for more updates as we continue to bring you the latest insights from the ever-evolving pharmaceutical and biotech industries.Support the show

In this series, the 2025-26 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.LuAnne Sirdiak spent a year waiting for her cancer to grow enough to qualify for a clinical trial. When she got in, she stayed on treatment longer than anyone else — long enough that her results changed how the trial was run.This is the final part of my conversation with LuAnne. We talk about what being in a trial did to her, and what it gave her: the say she had in her own treatment, the dose decisions she was part of, and what it means to her that the data from her body may help the people who come after. And we talk about the question every patient considering a trial eventually has to answer for themselves — knowing everything she knows now, and where she is today, would she do it again.Music: Ester - Here (BenSound) License certificate #2242649

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating updates that are shaping the future of medicine and patient care. First on our agenda is uniQure's ambitious step toward accelerated U.S. marketing approval for AMT-130, a gene therapy targeting Huntington's disease. This move signifies a potential breakthrough in treating rare neurological disorders with genetic roots. The approval of AMT-130 would highlight gene therapy's transformative power, not just for Huntington's disease but also for a broader range of genetic conditions, offering hope to patients where traditional treatments have fallen short. In the realm of oncology, Summit Therapeutics, in collaboration with Akeso, has reported that their bispecific antibody ivonescimab has surpassed Merck's Keytruda in a Phase 3 trial for non-small cell lung cancer. The trial revealed superior overall survival and progression-free survival rates, marking a significant milestone in cancer treatment. Bispecific antibodies like ivonescimab open new avenues for targeting multiple pathways simultaneously, potentially leading to more effective therapies with reduced side effects. Collaboration continues to be a pivotal strategy in drug development. GSK and Hutchmed have formed a licensing agreement for HMPL-A830, an innovative cancer therapy. This partnership involves an upfront payment of $110 million, with the potential to reach $1.3 billion based on performance milestones. Such alliances highlight the importance of strategic partnerships in accelerating therapeutic advancements and expanding the arsenal of available cancer treatments. Moving to regulatory milestones, Samsung Bioepis has secured approval in Japan for its biosimilar ustekinumab, aimed at treating moderate-to-severe Crohn's disease by targeting IL-12/IL-23 pathways. This approval is part of a larger trend towards biosimilars as cost-effective alternatives to biologics, increasing access to essential treatments for autoimmune diseases. In cardiovascular health, Everest Medicines has received China NMPA approval for Cardamyst (etripamil), a self-administered nasal spray for paroxysmal supraventricular tachycardia. The approval underscores innovations in patient-centric drug delivery systems that offer easier administration methods and empower patients to manage their conditions effectively. On the business front, Fortrea has acquired Worldwide Clinical Trials' early-phase division for $45 million. This acquisition aims to bolster Fortrea's clinical research organization platform, reflecting the growing demand for comprehensive clinical pharmacology services that can accelerate drug development timelines. Meanwhile, Pfizer's divestment of its Seagen antibody-drug conjugate PF-08046031 to Medicus Pharma in a deal exceeding $1 billion exemplifies strategic realignments within large pharmaceutical companies. These transactions allow companies to streamline operations and focus on core therapeutic areas where they can make the most impact. Research advancements are also making headlines as Revolution Medicines reports promising Phase 1/2 data for Rasonque (daraxonrasib) in NSCLC patients with KRAS mutations. KRAS has been notoriously difficult to target, so these findings highlight Rasonque's potential as a breakthrough small molecule therapy addressing critical needs in oncology. Despite these strides forward, challenges remain evident. Ultragenyx's GTX-102 did not meet primary or secondary endpoints in its Phase 3 Angelman syndrome study. This setback highlights the complexities involved in developing effective treatments for rare neurological conditions and underscores the inherent risks in high-stakes clinical trials. Turning our attention back to regulatory dynamics, FDA deliberations over Replimune's melanoma treatment revealed nuanced decision-making processes balancing clinical evaluation with strategic considerations. Even amidst internal disagreements, FDA leadership endorsed an accelerated nod for Replimune's therapy—an illustration of how complex these processes can be. In terms of funding innovation, ARPA-H's substantial $125 million investment into personalized RNA-based drug production reflects a commitment to advancing RNA therapeutics despite recent challenges. The initiative could become a catalyst for new approaches in personalized medicine by leveraging RNA technologies to tailor treatments more precisely to individual profiles. Additionally, Roche is making headway in obesity treatment with its UCN2 analog, which shows promise in reducing weight without sacrificing lean muscle mass—an essential factor given obesity's global health implications. This development may introduce new mechanisms of action that could revolutionize existing therapies by overcoming metabolic challenges inherent in obesity treatment. Overall, these developments underscore a dynamic period within the pharmaceutical and biotech sectors characterized by rapid scientific progress and strategic realignments responding to evolving market demands. As companies navigate these changes, their ability to leverage new technologies and refine their strategic focus will be crucial in maintaining competitive advantage and driving future growth—all while aiming to improve patient outcomes globally.Support the show

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of early-stage and locally advanced non–small cell lung cancer (NSCLC) for 2026, reflecting recent shifts in staging and perioperative therapy.The discussion began with histology, distinguishing adenocarcinoma (positive for TTF-1 and CK7) from squamous cell carcinoma (positive for p63 and p40). Turning to staging, Drs Armstrong and Tawagi emphasized the 9th edition of the lung cancer TNM staging system, noting that T categories are unchanged but N2 is now split into N2a and N2b, and M1c is now split into M1c1 and M1c2. They also stressed the importance of biomarker testing for PD-L1, EGFR, ALK, and RET.Regarding treatment, they explained that stage IA disease warrants surgery or stereotactic body radiation therapy without systemic therapy. In resectable disease that is 4 cm or larger or node-positive disease, driver mutations guide management: osimertinib (Tagrisso) for EGFR-mutated disease, alectinib (Alecensa) for ALK-positive disease, and selpercatinib (Retevmo) for RET-mutated disease, with immunotherapy avoided in EGFR-mutated or ALK-positive tumors. For driver-negative disease, they reviewed 4 category 1 regimens, including neoadjuvant nivolumab (Opdivo) and perioperative pembrolizumab (Keytruda) or nivolumab, cautioning against switching agents in the middle of a treatment course.Drs Armstrong and Tawagi then addressed adjuvant immunotherapy, unresectable stage III disease management with concurrent chemoradiation followed by consolidative durvalumab (Imfinzi) or osimertinib, surgical candidacy, adjuvant chemotherapy regimens, postoperative radiation, and special circumstances, including superior sulcus tumors.

This week's episode focuses on early-stage and locally advanced non-small cell lung cancer - staging, pathology, local and systemic therapy. Before we start, the usual caveat: the treatment landscape of NSCLC is changing FAST, which is exciting, but know that the boards run a few years behind. The big shifts since our last episode are the move to 9th-edition TNM staging and the arrival of four different perioperative chemo+immunotherapy regimens. Shout out to Dr. Bharathi Muthusamy for reviewing this episode to keep us current for 2026!

In this Korean-language episode of Lung Cancer Considered, Dr. Chul Kim is joined by Dr. Hye-Ryun Kim and Dr. Young Kwang Chae to discuss the evolving role of immunotherapy across the lung cancer treatment continuum. They explore perioperative strategies for resectable NSCLC, treatment selection and biomarkers in advanced disease, emerging research, and what they are looking forward to at WCLC 2026 in Seoul. Guest Host: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Guests: Hye Ryun Kim, MD, PhD Medical Oncologist Chief of Lung Cancer Center Yonsei Cancer Center Young Kwang Chae, MD, MPH, MBA Professor, Division of Hematology Oncology, Department of Medicine Northwestern University Feinberg School of Medicine

On this week's episode, Daphne Zohar, Eric Schmidt, Sam Fazeli, and Graig Suvannavejh open with a strong week for biotech, partially driven by M&A, noting it's already past 2025's full-year total. The group turns to Moderna, whose melanoma cancer vaccine data sent shares up nearly 200% and stirred some mixed feelings from investors. Contrastly, BioNTech's decision to halt its colorectal cancer vaccine trial was also noted. In data news, Revolution Medicines' FDA approval of daraxonrasib (RASONQUE) for pancreatic cancer drew attention for its potential first-line use and implications for trials behind it, while Akeso/Summit's ivonescimab was approved in China for NSCLC and also reported positive Phase 3 data in biliary tract cancer, reinforcing the case for VEGF/PD-1 bispecifics. Also in data news, AstraZeneca's full dataset of eplontersen for ATTR-CM raised doubts about the class of RNA-targeted silencers over currently marketed drugs that “silence” TTR proteins, while EyePoint's Phase 3 miss in wet AMD sent shares down about 70%. The conversation shifts to policy, where the group discusses pros and cons of FDA commissioner nominee Heidi Overton, the HHS plans for two new deputy roles, alongside concerns over declining U.S. IND filings versus China's rising trial volume. The episode concludes with Amylyx raising over $500 million on strong avexitide data in post-bariatric hypoglycemia, and J&J's Imaavy earning a second indication, expanding the anti-FcRn class. *This episode aired on August 28, 2026.

Highlights from the PER® CME activity "MET Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; and Anne S. Tsao, MD, MBA, discuss diagnostic and treatment strategies for patients with MET-altered non–small cell lung cancer.Earn CME credit by completing the full accredited activity (available through September 19, 2026): https://www.gotoper.com/courses/met-alterations-in-nsclc-applying-diagnostic-advances-and-targeted-therapies-in-a-new-era-of-treatment-vdpvThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AbbVie, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking updates that could significantly impact drug development and patient care. Vera Therapeutics recently announced promising Phase 3 clinical trial results for its monoclonal antibody, Trutakna, in treating immunoglobulin A nephropathy (IgAN). This kidney condition, marked by IgA protein accumulation leading to inflammation and renal failure, is a significant concern in nephrology. Trutakna's ability to stabilize kidney function positions it as a formidable competitor to existing treatments like Otsuka's Voyxact. These results highlight the potential of monoclonal antibodies in addressing complex kidney diseases by modulating proteinuria and preserving the estimated glomerular filtration rate (eGFR), crucial endpoints in evaluating kidney health. In oncology, AstraZeneca has made significant strides with its combination therapy of Tagrisso and Orpathys for patients with EGFR-mutated non-small cell lung cancer (NSCLC). The Phase 3 trial meeting its primary endpoints for progression-free survival and overall survival is a testament to the efficacy of integrating therapies targeting specific genetic mutations, such as EGFR and MET amplifications. This advancement underscores the growing importance of targeted cancer therapies in providing robust treatment options for patients with specific genetic markers. However, AstraZeneca faced a setback as it halted its Phase 3 trial of volrustomig after interim data showed no significant improvements in metastatic NSCLC outcomes, highlighting the challenges in oncology drug development. On the business front, Slate Medicines has successfully completed a reverse merger with Fulcrum Therapeutics, raising $245 million to further its migraine-targeting monoclonal antibody trials. This financial boost not only enhances their market position but also accelerates efforts in addressing neurological conditions known for their treatment challenges. The trend of leveraging monoclonal antibodies in neurological drug development reflects a broader industry focus on innovative therapeutic approaches. Regulatory developments are also shaping the landscape, with the FDA clearing Lantheus' Tauklarify, an imaging agent for tau pathology in Alzheimer's disease evaluation. This PET imaging agent could revolutionize Alzheimer's diagnosis and management by highlighting tau protein tangles central to disease progression. Meanwhile, Biogen has expanded its reach in China with approval for Jingfei (felzartamab), an anti-CD38 antibody used in multiple myeloma treatments, adding to the arsenal against this aggressive cancer type. Partnerships are fueling innovation across the industry. Saizen Therapeutics has entered into a $100 million milestone-driven collaboration with a San Diego biotech to develop oral peptides using AI/ML technologies. Eli Lilly's partnership with OmniAb on ion channel research could yield up to $370 million in milestones, emphasizing the potential of ion channels as drug targets. In ophthalmology, EyePoint's Duravyu failed to demonstrate non-inferiority compared to aflibercept in treating wet age-related macular degeneration, highlighting ongoing hurdles in drug development within this field. Companies like BioCryst Pharmaceuticals are pivoting towards external partnerships to expand their rare disease pipeline, reflecting broader trends towards strategic specialization and cost management. This shift underscores the dynamic interplay between scientific innovation and strategic business maneuvers within the industry. Turning our attention to psychedelic therapeutics, there is a resurgence of interest as these therapies approach potential regulatory approval. Compass Pathways is advancing its psilocybin-based candidate COMP360 through a rolling submission process aimed at treating treatment-resistant depression. With promising results from Phase 3 trials, COMP360 could soon join Johnson & Johnson's Spravato as a key player in this competitive landscape. Definium Therapeutics is also making headway with its LSD-based therapy DT120 for major depressive disorder and generalized anxiety disorder. Success in recent trials positions Definium well for filing a New Drug Application next year. The validation of these therapies by leading pharmaceutical companies underscores their growing significance in mental health treatment. Eli Lilly's acquisition of Ataibeckley for $3.8 billion highlights big pharma's recognition of psychedelics' potential as transformative mental health treatments. This acquisition follows other significant moves within the sector, signaling a pivotal moment for psychedelics in healthcare. As these developments unfold against a backdrop of technological transformation and strategic collaborations, they promise to shape future therapeutic landscapes significantly. The successful integration of innovative therapies into clinical practice could herald a new era in patient care worldwide. Stay tuned as we continue to bring you the latest insights from the rapidly evolving world of pharmaceuticals and biotech.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WHT865. CME credit will be available until August 5, 2027.Putting the Patient First: Optimising Shared Decision-Making for Unresectable Stage III EGFRm NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WHT865. CME credit will be available until August 5, 2027.Putting the Patient First: Optimising Shared Decision-Making for Unresectable Stage III EGFRm NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WHT865. CME credit will be available until August 5, 2027.Putting the Patient First: Optimising Shared Decision-Making for Unresectable Stage III EGFRm NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The discussion reviews advances in ALK+ non-small cell lung cancer (NSCLC).

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have showcased a dynamic landscape in these sectors, marked by scientific breakthroughs, regulatory updates, and strategic business decisions that are collectively reshaping the future of drug development and patient care. AstraZeneca recently faced challenges with its new blood pressure medication, Baxfendy, as it did not meet the cost-effectiveness standards set by the Institute for Clinical and Economic Review. This situation underscores the ongoing complexities surrounding drug pricing and value assessments, which remain critical for pharmaceutical companies trying to balance innovation costs with market demands. In the realm of rare diseases, Neurocrine Biosciences is under scrutiny over safety concerns related to its drug Vykat XR for Prader-Willi syndrome. Approved around 18 months ago, this situation highlights the intricate balance required in rare disease treatments where safety and efficacy must be meticulously managed. Legend Biotech is navigating a competitive landscape in CAR-T cell therapy, facing rising competition from T-cell engagers and new autologous CAR-T therapies by companies like Gilead. Despite this, Legend achieved a significant milestone by posting its first profitable quarter, signaling potential financial stability amidst intense competition in this innovative therapeutic area. The obesity treatment market is also evolving rapidly with increased demand for GLP-1 weight-loss drugs. Novo Nordisk's CEO has emphasized that obesity management isn't a zero-sum game, reflecting a broader trend towards personalized medicine where patient preferences are becoming more central to therapeutic development and marketing strategies. Leo Pharma is emphasizing education and awareness in managing rare dermatological conditions through its Generalized Pustular Psoriasis Awareness Day. Such initiatives are vital for fostering better understanding and improving patient outcomes in niche markets. In oncology, Cullinan Therapeutics and Taiho Pharmaceutical are advancing their small-molecule EGFR inhibitor after achieving Phase 3 success. This sets the stage for challenging established players like Johnson & Johnson in specific lung cancer niches. Their success underscores the importance of strategic partnerships and robust clinical trials in expanding cancer treatment options. Meanwhile, Akeso's approval of ivonescimab in China for squamous NSCLC highlights an innovative approach combining checkpoint inhibition with angiogenesis blockade. This dual-targeting strategy aims to enhance antitumor responses and improve survival outcomes in lung cancer patients. From a technological standpoint, artificial intelligence is making substantial inroads into healthcare delivery. AI-enabled tools are boosting hepatitis C cure rates by enhancing patient identification and reducing administrative burdens. This trend illustrates how AI is becoming integral to optimizing clinical outcomes and operational efficiencies within healthcare systems. The integration of AI into clinical trials promises to accelerate timelines and improve outcomes. Zealand Pharma strategically sold its rights to Takeda's blood cancer drug ahead of an FDA approval decision, demonstrating how companies navigate regulatory timelines to optimize their portfolios. Such maneuvers reflect broader trends within the pharmaceutical industry as companies increasingly focus on precision medicine and strategic acquisitions to bolster pipelines in niche markets like rare diseases. PTC Therapeutics recently acquired Sangamo Therapeutics' Fabry gene therapy program for an upfront payment of $111 million. This acquisition underscores PTC's strategic expansion into gene therapy for rare diseases, aiming to provide long-term solutions by addressing underlying genetic causes. As these developments unfold, they paint a picture of an industry poised at the intersection of cutting-edge science and innovative technology. Strategic investments in rare diseases and novel therapeutic approaches such as nanobodies are paving the way for groundbreaking treatments addressing unmet medical needs. Despite these promising advancements, challenges persist—such as those faced by Neurocrine Biosciences with safety concerns over Vykat XR—and highlight the inherent risks associated with drug development. Nonetheless, as companies continue to innovate and adapt strategies amidst evolving market dynamics, they hold promise for advancing patient care through cutting-edge therapies that emphasize precision medicine. As we continue to monitor these trends at Pharma Daily, it's clear that innovation coupled with strategic business decisions will define the trajectory of pharmaceutical and biotech industries as they strive to address unmet medical needs through research and tailored healthcare solutions. Stay tuned for more updates on how these developments impact patient care globally.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WHT865. CME credit will be available until August 5, 2027.Putting the Patient First: Optimising Shared Decision-Making for Unresectable Stage III EGFRm NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WHT865. CME credit will be available until August 5, 2027.Putting the Patient First: Optimising Shared Decision-Making for Unresectable Stage III EGFRm NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WHT865. CME credit will be available until August 5, 2027.Putting the Patient First: Optimising Shared Decision-Making for Unresectable Stage III EGFRm NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that underscore the dynamic shifts and groundbreaking progress within the industry. Recently, Akeso's ivonescimab received a landmark approval for first-line treatment of non-small cell lung cancer (NSCLC) in China. This marks a significant shift in China's regulatory environment, which is increasingly fostering innovative treatment options. Ivonescimab's approval not only enhances Akeso's standing in oncology but also provides new hope for NSCLC patients, a cancer type notoriously difficult to treat. In the arena of mergers and acquisitions, Alfasigma has strategically expanded its reach by acquiring key assets from Nordic Pharma. This acquisition opens doors to new therapeutic areas like arthritis, women's health, and critical care—an astute move to diversify offerings and enhance global market presence. Such strategic expansions are essential for companies aiming to maintain competitive edge and explore untapped markets. Eli Lilly has taken legal action against six U.S. companies involved in unauthorized sales of its experimental weight-loss drug, retatrutide. This highlights ongoing challenges in intellectual property protection, emphasizing the balance between innovation safeguarding and market expansion. The legal actions are part of broader efforts to preserve public safety and ensure proper distribution channels for groundbreaking therapies. On the quality control front, Fresenius faced a setback with the recall of a batch of Actemra biosimilars due to glass particle contamination concerns. This incident serves as a stark reminder of the critical role rigorous quality assurance plays in pharmaceutical manufacturing, especially as biosimilars gain traction for their cost-effectiveness and accessibility. In an intriguing blend of technology and healthcare, Samsung Electronics has secured FDA clearance for its Galaxy Buds earphones to function as over-the-counter hearing aids. This development illustrates the increasing convergence of consumer electronics with medical devices, offering innovative solutions to enhance accessibility in hearing health. Turning to psychedelic therapies, Definium Therapeutics reported significant success in its Phase 3 trials for an LSD-based formulation targeting generalized anxiety disorder. Building on earlier successes in depression studies, Definium is paving the way for psychedelic compounds in mainstream medicine. The results not only bolster confidence in such therapies but also signal a potential paradigm shift in treating mental health disorders. Moreover, Oracle Health has introduced an upgraded patient portal featuring an AI assistant designed to simplify medical records management and appointment scheduling. This advancement is part of a larger trend towards integrating artificial intelligence into healthcare systems to improve patient engagement and streamline processes, ultimately enhancing healthcare delivery efficiency. BridgeBio's ATTR stabilizer Attruby achieved impressive quarterly sales of $222 million, nearing blockbuster status as it captures significant market share in treating transthyretin amyloidosis (ATTR). This success underscores the growing importance of small molecule therapies in addressing complex cardiovascular conditions and reflects an industry trend towards stabilizer-first markets. InduPro has successfully raised $77 million in Series B funding supported by industry leaders like Sanofi and Lilly. The investment is set to propel their cancer pipeline forward with a focus on induced proximity and bispecific antibody platforms—innovations poised to revolutionize oncology treatment by enhancing drug specificity and efficacy. On the regulatory front, Chiesi UK's delayed-release mercaptamine received NHS endorsement for cystinosis treatment—an advancement that expands therapeutic options for patients requiring cystine-depleting therapy. Such regulatory support is crucial for facilitating access to innovative treatments for rare diseases. Amidst these developments, Gilead Sciences licensed MacroGenics' bispecific antibody program—a strategic move to bolster its oncology portfolio through milestone payments and royalties. This reflects a broader industry pattern where larger pharmaceutical companies seek pipeline diversification through strategic partnerships and acquisitions of innovative technologies. In vaccine development news, StablePharma's SPVX02 tetanus-diphtheria vaccine achieved promising Phase 1 results without refrigeration requirements—an innovation that could significantly enhance global vaccination efforts by overcoming cold chain distribution challenges. Finally, Insilico Medicine stands at the forefront of AI integration into drug discovery processes under CEO Alex Zhavoronkov's leadership. By promoting a 'fail-fast' approach at the Bio International Convention, Insilico aims to accelerate drug development timelines while reducing costs—a strategy indicative of biopharma's evolution towards more data-driven decision-making processes. These stories collectively highlight an era marked by rapid innovation within pharmaceuticals and biotech sectors. As companies navigate these complexities through scientific advancements and strategic maneuvers alike—there lies immense potential not only for enhancing patient care but also driving economic growth across global healthcare landscapes.Support the show

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC.Their discussion centered on the continued evolution of precision medicine in non–small cell lung cancer (NSCLC), highlighting advances in molecular testing, targeted therapies, immunotherapy, and emerging treatment strategies presented at the 2026 ASCO Annual Meeting. Drs Park and Liu explored how lung cancer has become a model for precision oncology and emphasized that therapeutic advances across multiple tumor types have collectively shaped the current treatment landscape. They discussed the importance of understanding oncogenic drivers, overcoming resistance mechanisms, and moving effective therapies into earlier-stage disease to improve long-term patient outcomes.

In today's episode, we spoke with Solange Peters, MD, PhD. Dr Peters is a full professor, and chair of medical oncology and the thoracic malignancies programme in the Department of Oncology at the University Hospital of Lausanne in Switzerland. In our exclusive interview, Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in non–small cell lung cancer (NSCLC), rather than sequencing them. She noted that prior attempts to combine or sequence bevacizumab (Avastin) with checkpoint inhibitors yielded only modest signals, hampered by bevacizumab's long half-life and class-specific toxicities including bleeding risk that historically excluded patients with squamous cell carcinoma. By contrast, PD-L1/VEGF bispecifics such as pumitamig carry a significantly shorter half-life of approximately 5 to 6 days, resulting in a similar toxicity category but with lower rates of high-grade events and a broadened eligible population.She highlighted the mechanistic rationale for this combination, explaining that VEGF and PD-L1 co-targeting appears to remodel the tumor microenvironment cooperatively, bringing cancer cells into closer proximity with T cells. In the case of PD-L1/VEGF bispecifics, a macromolecular structure forms in the tumor microenvironment that leads to internalization of PD-L1, creating a dual blockade of the PD-1/PD-L1 pathway beyond simple receptor occupancy.Dr Peters then discussed data presented at the 2026 ASCO Annual Meeting from the phase 2/3 ROSETTA Lung-02 trial (NCT06712316) evaluating pumitamig plus chemotherapy in the first-line setting. She described the activity observed across all PD-L1 expression strata, including in PD-L1–negative patients, who comprised up to 70% of the nonsquamous population and achieved response rates above 50% as particularly compelling. She also addressed the dose selection rationale, noting that the 1500-mg dose demonstrated the optimal pharmacodynamic activity and favorable risk-benefit profile for phase 3 advancement.Finally, Dr Peters offered broader perspective on the increasingly competitive PD-L1/VEGF bispecific landscape, including the parallel development of ivonescimab. She suggested that differences in clinical trial design including patient population, inclusion and exclusion criteria, and end point ambition may ultimately differentiate agents more than mechanism alone, and emphasized that global data will be essential to shaping regulatory and clinical practice decisions.

Featuring perspectives from Dr Joshua K Sabari, including the following topics: Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00) Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study. ESMO 2025;Abstract 2020P. (8:30) Schram AM et al. Beamion PANTUMOR-1: Rationale and design of a phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol 2026;22(7):795-803. (12:53) Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654. (19:40) Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648. (21:41) Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137. (22:59) Jänne PA et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic NSCLC with or without brain metastases: A secondary analysis of randomized clinical trials. JAMA Netw Open 2025;8(11):e2543107. (24:37) CME information and select publications

Dr. Sonam Puri joins the podcast to share the update to the living guideline on stage IV NSCLC with driver alterations. Dr. Puri discusses the practice-changing evidence reviewed for both NTRK rearrangements, including the TRIDENT-1 trial, and HER2 activating mutations, including the Beamion LUNG-1 study. She shares how these results impacted the clinical practice guideline with the addition of repotrectinib and zongertinib, what these new TKIs mean for patients, and where the panel is waiting for additional randomized data to clarify the role of therapeutic options. Dr. Puri encourages listeners to stay tuned for future updates to the living guideline as new evidence is published. Read the full living guideline "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2" at www.ascopubs.org/guidelines/therapy-stage-iv-non-small-cell-lung-cancer-driver-alterations" LINK TO FULL TRANSCRIPT

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Rosario Charo Garcia Campelo, MD Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pretreated metastatic pancreatic cancer treatment, daraxonrasib.  

This episode reviews new evidence supporting extended DAPT beyond one year for selected patients after multivessel PCI, the role of MRD-guided decisions for maintenance lenalidomide in multiple myeloma, adjuvant ensartinib for resected ALK-positive NSCLC, and emerging data on semaglutide and combination therapy for MASH-related cirrhosis. The studies highlight how precision medicine continues to refine treatment duration, biomarker-driven care, and therapeutic selection across multiple specialties.

Highlights from the PER® CME activity "Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; and Paula A. Ugalde Figueroa, MD; discuss evolving immunotherapy strategies for stage I to III non–small cell lung cancer (NSCLC), spanning surgical work-up and the shifting definition of resectability, perioperative immunotherapy trial data, the way that pathologic response guides treatment decisions, and the integration of radiation with immunotherapy in unresectable disease.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/tumor-board-evolving-immunotherapy-strategies-for-stage-i-iii-nsclc-1This podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AstraZeneca Pharmaceuticals.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Justin Gainor, MD; Julia Rotow, MD; and Urs Weber, MD; discuss targeted therapies and immunotherapy to treat advanced non-small cell lung cancer (NSCLC).Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/tumor-board-optimizing-nsclc-careleveraging-the-latest-evidence-on-targeted-therapy-and-immuno-oncology-1fgrThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from BioNTech; Iovance Biotherapeutics, Inc; Lilly; Nuvation Bio; Revolution Medicines, Inc; and Rigel Pharmaceuticals.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics: ·      Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00) ·      Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07) ·      Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50) CME information and select publications

Featuring an interview with Dr Jamie E Chaft, including the following topics: Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00) Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45) Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39) Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28) Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03) Importance of clinical trials in the adjuvant setting (33:02) Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41) Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34) Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01) CME information and select publications

Highlights from the PER® CME activity "Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, focusing on precision oncology in non-small cell lung cancer (NSCLC), experts Helena Yu, MD; Jacob Sands, MD; and Sarah Goldberg MD, MPH; will discuss the rapidly evolving landscape of Human Epidermal growth factor Receptor 2 (HER2)- and Trophoblast cell-surface antigen 2 (TROP2)-directed therapies in NSCLC. The podcast covers the spectrum of targeted agents from antibody-drug conjugates (ADCs) to novel HER2-selective tyrosine kinase inhibitors (TKIs), along with key clinical trial data and practical strategies for managing the unique adverse event profiles associated with these treatments.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-care-mr5qThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.